Strides Pharma Science shares zoom 20% after company develops Favipiravir antiviral tablets
Shares of Strides Pharma Science Ltd on Wednesday zoomed 20 percent after the company said it has developed and commercialised Favipiravir antiviral tablets, and stressed that the drug has demonstrated positive outcomes in COVID-19 treatment globally
New Delhi: Shares of Strides Pharma Science Ltd on Wednesday zoomed 20 percent after the company said it has developed and commercialised Favipiravir antiviral tablets, and stressed that the drug has demonstrated positive outcomes in COVID-19 treatment globally.
The scrip advanced 20 percent to close at Rs 449.10, its upper circuit, on the BSE.
At the NSE, it climbed 20 percent to close at Rs 449.60.
"Favipiravir is an antiviral medication that was initially developed to treat influenza in Japan. In February 2020, post the outbreak of Novel Coronavirus (COVID-19), Favipiravir was studied in China and several other countries as an experimental treatment of COVID-19," the company said in a filing to the BSE.
"The drug has demonstrated positive outcomes, including a reduction in the duration of COVID-19 and improved lung conditions for the patients," it added.
It said Strides is the first Indian company to have commenced the export of Favipiravir tablets.
Videos on Chinese social media that said they were filmed at the factory in the central city of Zhengzhou showed thousands of people in masks facing rows of police in white protective suits with plastic riot shields. Postings on social media said they were protesting unspecified contract violations
As 1.2 million football enthusiasts gather in Qatar for the FIFA World Cup 2022, the WHO has warned of a possible outbreak of camel flu, also known as the Middle East Respiratory System (MERS). Considered to be a deadlier cousin of COVID-19, it kills up to a third of those who get infected
'Covid was man-made virus', claims former Wuhan Lab Scientist in his new book 'The Truth About Wuhan'
Huff reportedly alleges in his book that China's gain-of-function experiments were carried out with insufficient security, leading to a leak at the Wuhan lab